University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Jeffrey Tice, MD

Jeffrey Tice, MD

Associate Professor, Department of Medicine (General Internal Medicine), UCSF

Cancer Center Program Memberships

Breast Oncology

Education

Dartmouth College, Hanover, NH, BA, 06/1983, Math; Philosophy
San Francisco State University, 05/1989, Pre-medical classed
University of California, San Francisco, MD, 06/1994, Medicine
University of California, San Francisco, 06/1997, Internal Medicine
University of California, San Francisco, Postdoctoral, 06/1999, Research/Epidmiology


Professional Experience

  • 1984-1986
    Peace Corps Volunteer, Bangassou, Central African Republic
  • 1987 - 1992
    Programmer/Analyst III, Department of Epidemiology, University of California, San Francisco
  • 1999-2004
    Assistant Adjunct Professor of Medicine, Division of General Internal Medicine, Department of Medicine, University of California, San Francisco
  • 2005-2011
    Assistant Professor of Medicine, Division of General Internal Medicine, Department of Medicine, University of California, San Francisco
  • 2012-present
    Associate Professor of Medicine, Division of General Internal Medicine, Department of Medicine, University of California, San Francisco

Honors & Awards

  • 2013
    UCSF Research Mentoring Award
  • 2009
    Society of General Internal Medicine- CA Region- Outstanding Clinician Investigator Award
  • 2003
    Robert Crede Award for Clinical Research, UCSF Division of General Internal Medicine
  • 2002-2004
    Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Faculty Scholar
  • 1994
    Alpha Omega Alpha, UCSF
  • 1990-1994
    Regents Scholarship, UCSF
  • 1983
    Summa Cum Laude, Dartmouth College
  • 1982
    Phi Beta Kappa, Dartmouth College
  • 1979-1983
    Rufous Choate Scholar, Dartmouth College
  • 1979-1983
    IBM Thomas J. Watson Scholar

Selected Publications

  1. Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. JAMA. 2017 08 22; 318(8):748-750.
    View on PubMed
  2. Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JWT, Tice JA, Ziv E, Kerlikowske K, Cummings SR. Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. Breast Cancer Res Treat. 2017 Aug 08.
    View on PubMed
  3. Tice JA, Kerlikowske K. Supplemental Breast Cancer Screening: A Density Conundrum. J Gen Intern Med. 2017 Jun; 32(6):593-594.
    View on PubMed
  4. Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. J Natl Cancer Inst. 2017 01; 109(5).
    View on PubMed
  5. Ziv E, Tice JA, Sprague B, Vachon CM, Cummings SR, Kerlikowske K. Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention. PLoS One. 2017; 12(1):e0168601.
    View on PubMed
  6. Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL. Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer. J Natl Cancer Inst. 2017 05; 109(5).
    View on PubMed
  7. Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017 Feb; 118(2):220-225.
    View on PubMed
  8. Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JW, Tice JA, Vachon CM, Cummings SR, Kerlikowske K, Ziv E. Breast cancer risk prediction using a clinical risk model and polygenic risk score. Breast Cancer Res Treat. 2016 Oct; 159(3):513-25.
    View on PubMed
  9. Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA. 2016 Aug 16; 316(7):743-53.
    View on PubMed
  10. Reed SJ, Shore KK, Tice JA. Effectiveness and Value of Integrating Behavioral Health Into Primary Care. JAMA Intern Med. 2016 May 01; 176(5):691-2.
    View on PubMed
  11. Dallal CM, Lacey JV, Pfeiffer RM, Bauer DC, Falk RT, Buist DS, Cauley JA, Hue TF, LaCroix AZ, Tice JA, Veenstra TD, Xu X, Brinton LA. Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the B ~ FIT Cohort. Horm Cancer. 2016 Feb; 7(1):49-64.
    View on PubMed
  12. Tice JA, Kazi DS, Pearson SD. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value. JAMA Intern Med. 2016 Jan; 176(1):107-8.
    View on PubMed
  13. Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med. 2016 Jan; 176(1):65-73.
    View on PubMed
  14. Livaudais-Toman J, Karliner LS, Tice JA, Kerlikowske K, Gregorich S, Pérez-Stable EJ, Pasick RJ, Chen A, Quinn J, Kaplan CP. Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: A randomized, controlled trial. Breast. 2015 Dec; 24(6):758-66.
    View on PubMed
  15. Tice JA, Chahal HS, Ollendorf DA. Comparative Clinical Effectiveness and Value of Novel Interferon-Free Combination Therapy for Hepatitis C Genotype 1: Summary of California Technology Assessment Forum Report. JAMA Intern Med. 2015 Sep; 175(9):1559-60.
    View on PubMed
  16. Hart V, Reeves KW, Sturgeon SR, Reich NG, Sievert LL, Kerlikowske K, Ma L, Shepherd J, Tice JA, Mahmoudzadeh AP, Malkov S, Sprague BL. The effect of change in body mass index on volumetric measures of mammographic density. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1724-30.
    View on PubMed
  17. Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K. Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. J Clin Oncol. 2015 Oct 01; 33(28):3137-43.
    View on PubMed
  18. Falk RT, Dallal CM, Lacey JV, Bauer DC, Buist DS, Cauley JA, Hue TF, LaCroix AZ, Tice JA, Pfeiffer RM, Xu X, Veenstra TD, Brinton LA. Estrogen Metabolites Are Not Associated with Colorectal Cancer Risk in Postmenopausal Women. Cancer Epidemiol Biomarkers Prev. 2015 Sep; 24(9):1419-22.
    View on PubMed
  19. Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, Miglioretti DL. Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med. 2015 May 19; 162(10):673-81.
    View on PubMed
  20. Kerlikowske K, Gard CC, Sprague BL, Tice JA, Miglioretti DL. One versus Two Breast Density Measures to Predict 5- and 10-Year Breast Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2015 Jun; 24(6):889-97.
    View on PubMed

Go to UCSF Profiles, powered by CTSI